Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 20, 2020
Reporting Period: Event date July 20, 2020; Signed July 24, 2020.
Business Context: The Company is an emerging growth company incorporated in Delaware, with common stock (Symbol: MBIO) traded on the NASDAQ Global Market.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain periodic financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
At-the-Market Offering Launch: On July 20, 2020, the Company launched an at-the-market offering program to sell up to $50,605,000 worth of its common stock.
- Agreement: The offering is conducted pursuant to an At Market Issuance Sales Agreement originally dated July 27, 2018, and amended on July 20, 2020.
- Agents: The sales agents include B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation, and Oppenheimer & Co. Inc.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the amended sales agreement to facilitate the equity offering. No specific forward-looking guidance regarding product development, clinical trials, or financial projections is included in this specific report.
Risks and Contingencies: The filing notes the delivery of a legal opinion by Alston & Bird LLP regarding the validity of the Offering. No other specific risks or contingencies are detailed in the text of this report.
Key Facts for Investor Verification
- Verify the total amount of shares sold and proceeds received under the $50,605,000 at-the-market offering program in subsequent filings.
- Review the full text of the "Amendment No. 1 to At Market Issuance Sales Agreement" (Exhibit 1.2) for specific terms, commissions, and termination rights.
- Monitor the Company's cash position and burn rate in upcoming quarterly reports (10-Q) to assess the impact of this capital raise on liquidity.
- Confirm the dilution impact on existing shareholders as shares are issued under this program.